You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B cell activation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Highly Sensitized Prospective Kidney Transplant Recipients Trial in San Francisco (daratumumab, belatacept, Bone marrow

Recruiting
  • Highly Sensitized Prospective Kidney Transplant Recipients
  • daratumumab
  • +2 more
  • San Francisco, California
    University of California at San Francisco Medical Center
Jan 27, 2022

Pulmonary Artery Hypertension Trial (XBD173)

Not yet recruiting
  • Pulmonary Artery Hypertension
  • (no location specified)
Sep 6, 2023

Mast Cell Activation Syndrome in EDS With Digestive Disorders

Recruiting
  • Ehlers Danlos Hypermobile Syndrome
  • Determine the presence of mast cell activation syndrome
  • Lille, Nord, France
    Saint-Vincent-de-Paul hospital
Jan 10, 2023

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

B-cell Lymphoma Trial in Stockholm, Uppsala (CAR20(NAP)-T, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • B-cell Lymphoma
  • CAR20(NAP)-T
  • +2 more
  • Stockholm, Sweden
  • +1 more
Aug 15, 2023

Sleep Apnea Trial in Halifax (NovaResp MAPR System)

Not yet recruiting
  • Sleep Apnea
  • NovaResp MAPR System
  • Halifax, Nova Scotia, Canada
    Sleep Disorders Clinic
Aug 14, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

Recruiting
  • B-Cell Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Nov 28, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)

Not yet recruiting
  • Hematopoietic Stem Cell Transplantation
  • Hematologic Malignancy
  • CliniMACS®
  • (no location specified)
Oct 17, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Not yet recruiting
  • Lymphoma, B-Cell
  • +6 more
  • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
  • Guayaquil, Guayas, Ecuador
    Instituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023

Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4 Trial in Nieuwegein, Rotterdam (CKD dashboard)

Completed
  • Chronic Kidney Disease Stage 3B
  • Chronic Kidney Disease stage4
  • CKD dashboard
  • Nieuwegein, Utrecht, Netherlands
  • +1 more
Jun 26, 2023

B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • SHR-A1912; R-Chemo
  • (no location specified)
Oct 23, 2023

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

Health Technology Intervention on Patient Activation in Multiple

Not yet recruiting
  • Multiple Myeloma in Relapse
  • +3 more
    • (no location specified)
    Jan 9, 2023

    Lymphoma Trial in Japan (Parsaclisib)

    Active, not recruiting
    • Lymphoma
    • Aichi, Japan
    • +5 more
    Jul 28, 2022

    Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

    Not yet recruiting
    • Lymphoma, B-Cell
    • +7 more
    • Adaptive Bridging Radiation Therapy (ABRT)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 16, 2023